There Are At Least 144 Candidates in the Breast Cancer Pipeline of Which, 26% Are Molecular Targeted Therapeutics (MTTs) - Pipeline Insight: Breast Cancer.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41990) has announced the addition of Pipeline Insight: Breast Cancer - A Diverse & Increasingly Crowded Pipeline to their offering. Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 447,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet un·met adj. Not satisfied or fulfilled: unmet demands. needs still persist for this tumor tumor: see neoplasm. type. Despite recent drug approvals in the adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. and metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. setting, the overall survival remains below five years. Scope of this title: --Overview of breast cancer and the current treatment options, including profiles and analysis of existing drugs --Insightful analysis of clinical trial data for late-phase drugs in development for breast cancer --Future global sales of key pipeline drugs for breast cancer to 2016, including their clinical/research and commercial attractiveness - The assessment of the clinical and commercial potential of the drugs currently in development for breast cancer Highlights of this title: --There are at least 144 candidates in the breast cancer pipeline of which, 26% are molecular targeted therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. (MTTs). Due to the cytostatic cytostatic /cy·to·stat·ic/ (sit?ah-stat´ik) 1. suppressing the growth and multiplication of cells. 2. an agent that so acts. cy·to·stat·ic adj. 1. nature of several MTTs, significant tumor regressions will likely be achieved when combined with cytotoxics. As cytotoxics comprise one-third of the pipeline, they will remain the backbone of treatment. - the author believes Genentech/Roches Avastin (bevacizumab) will earn blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. status within the breast cancer market. Unlike Herceptin, Avastin is not limited to HER-2 positive tumors and will have a major impact on first-line metastatic disease. Avastin will dominate the breast cancer market with 2016 sales approaching $1.5bn. - GlaxoSmithKlines Tykerb (lapatinib) will expand treatment options for HER-2 positive, Herceptin-refractory, locally advanced and metastatic patients, with approval likely by early-2007. As an estimated 40% of patients are Herceptin-refractory, Tykerbs sales could reach over $500m by 2016 in this setting alone. Reasons to order your copy: --Assess opportunities and risks in the breast cancer market by analyzing the clinical and commercial attractiveness of key agents --Evaluate the potential of your product in the breast cancer market by examining key pipeline drug sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. --Determine the commercial impact of new molecular-targeted agents entering the breast cancer market and their effects on current treatment paradigms Chapters are entitled en·ti·tle tr.v. en·ti·tled, en·ti·tling, en·ti·tles 1. To give a name or title to. 2. To furnish with a right or claim to something: as follows: Chapter 1 Executive summary Chapter 2 Pipeline overview and future focus Chapter 3 Pipeline dynamics Chapter 4 R&D approach Chapter 5 Cytotoxics late-stage drug analysis & forecasts 81 Chapter 6 Antihormonal drug analysis & forecasts Chapter 7 Molecular targeted therapies drug analysis & forecasts Chapter 8 Miscellaneous late-stage drug analysis & forecasts APPENDIX A List of Tables List of Figures For more information visit http://www.researchandmarkets.com/reports/c41990 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion